Journal of Applied Physiology Millar Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 104: 573-574, 2008. First published January 3, 2008; doi:10.1152/japplphysiol.01376.2007
8750-7587/08 $8.00
This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
104/3/573    most recent
01376.2007v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Konhilas, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Konhilas, J. P.

INVITED EDITORIALS

What makes a dead cell attractive?

John P. Konhilas

Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado

CONGESTIVE HEART FAILURE represents the end stage of various cardiac disease etiologies, including hypertension, myocardial infarction/ischemia from atherosclerosis, viral myocarditis, valvular insufficiency, or mutations in genes encoding sarcomeric proteins (1, 10, 11). These events trigger neurohumoral and cellular signaling cascades, ultimately resulting in myocardial adaptation, typically cardiac growth or hypertrophy, to compensate for any contractile detriments imparted by the disease. The transition from compensated to decompensated cardiac hypertrophy signifies a critical step in the progression to heart failure. However, as pharmacological and surgical treatment modalities improve mortality from cardiovascular disease, this transition becomes prolonged and less clearly defined, resulting in an ever-increasing clinical diagnosis of heart failure (10).

Multiple mechanisms have been implicated in the progressive deterioration of contractile function during heart failure, such as desensitization of β-adrenergic receptor signaling, dysregulation of excitation-contraction coupling, and activation of aberrant signaling pathways (6, 8, 12). In addition, experimental evidence exists for a causal role of myocardial cell loss as a mechanism underlying this transition to heart failure (for review, see Ref. 4). Cardiac cell death can occur by two primary mechanisms, apoptosis or necrosis. Although apoptosis is accepted as the more prominent mode of cell death (4, 7), necrosis has gained acceptance as a significant mediator of heart failure (13). Apoptosis is a highly regulated process of cell suicide that is mediated by extrinsic (ligand dependent) and intrinsic (mitochondrial dependent) pathways (4). Necrotic cell death is initiated by ischemic injury or perturbations in Ca2+ signaling accompanied by depletion of high-energy stores (3). Whereas necrosis immediately results in mitochondrial swelling and cell rupture, stimulating a robust inflammatory response, apoptotic cells are rapidly removed, presumably by phagocytotic processes following activation of the death signal (14, 15).

Clearance of apoptotic cells is an active process and involves alterations in cell surface motifs such as exposure of phosphatidylserine, leading to recognition by phagocytes (9). In their study in the Journal of Applied Physiology, Kobara et al. (7a) demonstrate that apoptotic cells may recruit phagocytotic cells through the release of chemokines, specifically monocyte chemoattractant protein-1 (MCP-1). MCP-1 regulates the recruitment of inflammatory cells into tissue during acute inflammatory events (2). In this study (7a), in vitro treatment of rat neonatal ventricular myocytes with staurosporine induces a robust and dose-dependent apoptotic response. These cells show an elevation of MCP-1 gene expression with concomitant MCP-1 protein expression. Interestingly, the culture medium from the staurosporine-treated cells is able to recruit more monocytes than that from the control cells. The authors also suggest that this upregulation may be initiated by interleukin-1, a well-known inducer of MCP-1 (16).

Next, to test the relevance of these in vitro findings to the intact heart, the authors exposed the hearts of male rats to an ischemia-reperfusion protocol. Following 24 h of reperfusion, the ischemic border region demonstrates significant apoptosis as detected by both terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL)-positive cells and DNA fragmentation. Furthermore, MCP-1 protein is evident along with infiltrating monocytes in this ischemic region.

The studies performed by Kobara et al. (7a) demonstrate two novel points: 1) the production and release of a soluble factor that may contribute to the clearance of apoptotic cells, and 2) a point of overlap between apoptotic and necrotic cell death. The first point contradicts previous work that found no evidence for the release of a soluble factor by apoptotic cells (5, 17). Regarding the second point, even though distinct signaling pathways mediate the initiation of apoptosis and necrosis, the recognition and clearance of "dying" cells involve a common inflammatory chemokine, MCP-1. Kobara et al. (7a) demonstrate that apoptotic cells express relatively more MCP-1 than necrotic cells, suggesting that MCP-1 may be playing different roles in these cell types. The differences between these two processes may result from the timing by which the cells are cleared. More studies examining the dynamics of apoptotic and necrotic cell clearance will more clearly elucidate this contention.

FOOTNOTES


Address for reprint requests and other correspondence: J. P. Konhilas, Dept. of Molecular, Cellular, and Developmental Biology, Univ. of Colorado, Boulder, CO 80309 (e-mail: John.Konhilas{at}colorado.edu)

REFERENCES

  1. Adams KF Jr. New epidemiologic perspectives concerning mild-to-moderate heart failure. Am J Med 110, Suppl 7A: 6S–13S, 2001.
  2. Castellani ML, Bhattacharya K, Tagen M, Kempuraj D, Perrella A, De Lutiis M, Boucher W, Conti P, Theoharides TC, Cerulli G, Salini V, Neri G. Anti-chemokine therapy for inflammatory diseases. Int J Immunopathol Pharmacol 20: 447–453, 2007.[Web of Science][Medline]
  3. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 116: 205–219, 2004.[CrossRef][Web of Science][Medline]
  4. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 115: 565–571, 2005.[CrossRef][Web of Science][Medline]
  5. Hughes J, Liu Y, Van Damme J, Savill J. Human glomerular mesangial cell phagocytosis of apoptotic neutrophils: mediation by a novel CD36-independent vitronectin receptor/thrombospondin recognition mechanism that is uncoupled from chemokine secretion. J Immunol 158: 4389–4397, 1997.[Abstract]
  6. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341: 1276–1283, 1999.[Free Full Text]
  7. Kajstura J, Cheng W, Sarangarajan R, Li P, Li B, Nitahara JA, Chapnick S, Reiss K, Olivetti G, Anversa P. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am J Physiol Heart Circ Physiol 271: H1215–H1228, 1996.[Abstract/Free Full Text]
  8. Kobara M, Sunagawa N, Abe M, Tanaka N, Toba H, Hayashi H, Keira N, Tatsumi T, Matsubara H, Nakata T. Apoptotic myocytes generate monocyte chemoattractant protein-1 and mediate macrophage recruitment. J Appl Physiol (November 29, 2007). doi:10.1152/japplphysiol.00254.2007.[Abstract/Free Full Text]
  9. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation 101: 1634–1637, 2000.[Free Full Text]
  10. Li MO, Sarkisian MR, Mehal WZ, Rakic P, Flavell RA. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science 302: 1560–1563, 2003.[Abstract/Free Full Text]
  11. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106: 3068–3072, 2002.[Abstract/Free Full Text]
  12. Maass A, Konhilas JP, Stauffer BL, Leinwand LA. From sarcomeric mutations to heart disease: understanding familial hypertrophic cardiomyopathy. Cold Spring Harb Symp Quant Biol 67: 409–415, 2002.[CrossRef][Web of Science][Medline]
  13. Marks AR. Ryanodine receptors, FKBP12, and heart failure. Front Biosci 7: d970–d977, 2002.[Web of Science][Medline]
  14. Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, Jaleel N, Chua BH, Hewett TE, Robbins J, Houser SR, Molkentin JD. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 117: 2431–2444, 2007.[CrossRef][Web of Science][Medline]
  15. Platt N, da Silva RP, Gordon S. Recognizing death: the phagocytosis of apoptotic cells. Trends Cell Biol 8: 365–372, 1998.[CrossRef][Web of Science][Medline]
  16. Ren G, Dewald O, Frangogiannis NG. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy 2: 242–256, 2003.[CrossRef][Medline]
  17. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mantovani A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb 11: 1166–1174, 1991.[Abstract/Free Full Text]
  18. Witting A, Muller P, Herrmann A, Kettenmann H, Nolte C. Phagocytic clearance of apoptotic neurons by microglia/brain macrophages in vitro: involvement of lectin-, integrin-, and phosphatidylserine-mediated recognition. J Neurochem 75: 1060–1070, 2000.[CrossRef][Web of Science][Medline]




This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
104/3/573    most recent
01376.2007v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Konhilas, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Konhilas, J. P.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.